Quang X. Pham - 09 Oct 2026 Form 4 Insider Report for Cadrenal Therapeutics, Inc. (CVKD)

Reporting relationship: Chairman and CEO, Director, 10%+ Owner
Issuer ticker: CVKD
Reported as of: 09 Oct 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 13 Oct 2026, 17:33:28 UTC
Prior SEC filing: 01 Jul 2026
Source filing: View source filing
Reporting owner signature: /s/ Quang X. Pham

Key filing fact

Quang X. Pham filed Form 4 for Cadrenal Therapeutics, Inc. (CVKD) on 13 Oct 2026.

Key facts

This page summarizes Quang X. Pham's Form 4 filing for Cadrenal Therapeutics, Inc. (CVKD).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 13 Oct 2026, 17:33.

Change

Previous filing in this sequence was filed on 01 Jul 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001405290 Primary reporting owner

Pham Quang X

Relationship: Chairman and CEO, Director, 10%+ Owner
Address: C/O CADRENAL THERAPEUTICS, INC., 822 A1A NORTH, SUITE 306, PONTE VEDRA
Signature: /s/ Quang X. Pham
Signature date: 13 Oct 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CVKD transaction Derivative

Stock Option

Award

Transaction value
Shares: +200,000
Change %
Price: $0.000000^*
Shares after: 200,000
Date: 09 Oct 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 200,000
Exercise price: $0.9100
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The stock options have a grant date of October 9, 2026 under the Issuer's 2022 Successor Equity Incentive Plan, were fully vested and immediately exercisable on the date of grant, and have an exercise price equal to the closing price of the Issuer's common stock on October 9, 2026.